Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. by Launay, Jean-Marie et al.
Serotonin 5-HT2B receptors are required for
bone-marrow contribution to pulmonary arterial
hypertension.
Jean-Marie Launay, Philippe Herve´, Jacques Callebert, Ziad Mallat, Corinne
Collet, Ste´phane Doly, Arnauld Belmer, Silvina Diaz, Sarah Hatia, Francine
Coˆte´, et al.
To cite this version:
Jean-Marie Launay, Philippe Herve´, Jacques Callebert, Ziad Mallat, Corinne Collet, et al..
Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary ar-
terial hypertension.. Blood, American Society of Hematology, 2012, 119 (7), pp.1772-80.
<10.1182/blood-2011-06-358374>. <inserm-00996752>
HAL Id: inserm-00996752
http://www.hal.inserm.fr/inserm-00996752
Submitted on 3 Mar 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Launay  p1 
 
Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial 
hypertension 
 
Jean-Marie Launay1, Philippe Hervé2, Jacques Callebert1, Ziad Mallat3, Corinne Collet1, Stéphane Doly4, 
Arnauld Belmer4, Silvina L. Diaz4, Sarah Hatia5, Francine Côté5, Marc Humbert6 and Luc Maroteaux4. 
 
Short title: Serotonin 5-HT2B receptor in bone-marrow and lung 
 
1AP-HP, Hôpital Lariboisière, Service de Biochimie, Paris, F-75010 France; INSERM U942, Paris, F-
75010 France. 2Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson – France. 3INSERM U970, 
PARCC, Hopital Européen Georges Pompidou, Paris, F-75015, France. 4INSERM UMR-S 839, F75005, 
Paris, France; Université Pierre et Marie Curie, F75005, Paris; Institut du Fer à Moulin, F75005, Paris. 
5CNRS UMR 8147, Paris, F-75015 France; Université Paris Descartes, F75015, Paris. 6Université Paris-
Sud 11, INSERM U999, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, AP-
HP,  Clamart – France. 
 
Correspondence and requests for materials should be addressed to L.M. (INSERM UMR-S 839, Institut du 
Fer à Moulin, 17 rue du Fer a moulin 75005, Paris FRANCE, Tel 331 45 87 61 23, Fax 331 45 87 61 32, E-
mail: luc.maroteaux@upmc.fr). 
 
Classification: Vascular biology 
word counts text 5100w, abstract 188w, figure count 6, reference count 47 
Launay  p2 
Abstract 
 
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by lung endothelial 
dysfunction and vascular remodeling. Recently, bone-marrow progenitor cells have been localized to PAH 
lungs, raising questions about their role in disease progression. Independently, serotonin (5-HT) and its 
receptors have been identified as contributors to the PAH pathogenesis. We hypothesized that one of these 
receptors, the 5-HT2B receptor, is involved in bone-marrow stem cell mobilization that participate to the 
development of PAH and pulmonary vascular remodeling. A first study revealed expression of 5-HT2B 
receptors by circulating c-kit+ precursor cells, while mice lacking 5-HT2B receptors showed alterations in 
platelets and monocyte-macrophages number and in myeloid lineages of bone-marrow. Strikingly, mice 
with restricted expression of 5-HT2B receptors on bone-marrow cells developed hypoxia- or monocrotaline-
induced increase in pulmonary pressure and vascular remodeling, while restricted elimination of 5-HT2B 
receptors on bone-marrow cells confers a complete resistance. Moreover, ex vivo culture of human CD34+ 
or mice c-kit+ progenitor cells in the presence of a 5-HT2B receptor antagonist resulted in altered myeloid 
differentiation potential. Thus, we demonstrate that activation of 5-HT2B receptors on bone-marrow lineage 
progenitors is critical for the development of PAH.  
 
Keywords: Bone-marrow transplant; genetics; pulmonary hypertension; receptors; hypoxia. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a rare but fatal disease, often of unknown origin, characterized by 
progressive increase in pulmonary vascular resistance and remodeling associated with vasoconstriction 1. 
PAH is histologically characterized by a neomuscularization of small pulmonary arteries with intimal 
thickening, medial hypertrophy, adventitial proliferation, and abnormal extracellular matrix deposition. The 
progression of vascular remodeling results in vascular lumen narrowing, increased pulmonary artery 
resistance, hypoxia, and right heart hypertrophy, although the molecular pathways initiating this remodeling 
are not clearly established.  
 On the one hand, stem cells, resident or not, may give rise to a significant proportion of 
differentiating/proliferating smooth muscle cells (SMC) that contribute to intimal hyperplasia in lung 
vascular remodeling 2. Moreover, genetic ablation of the transmembrane tyrosine kinase receptor for stem 
cell factor/c-kit pathway results in a marked reduction in intimal hyperplasia in animal models of vascular 
injury; conversely, wild-type (WT) bone-marrow reconstitution in c-kit mutant mice led to intimal 
hyperplasia comparable to WT animals 3. Pharmacological antagonism of the c-kit pathway with STI-571 
(imatinib mesylate-Gleevec) also results in a marked reduction in hyperplasia 3. Mobilization of c-kit 
expressing cells from bone-marrow to blood circulation is a physiological response to hypoxia. Increasing 
evidence supports the idea that these progenitor cells of bone-marrow origin may also contribute to vascular 
wall remodeling that is characteristic of PAH 4-8. It is unclear, however, whether this entry of progenitors 
represents a protective or a worsening process in the development of PAH 9. Other observations have also 
identified an association between PAH and bone-marrow-related hematological disorders 10: in proliferative 
disorders of the hematopoietic stem cells such as myeloproliferative cancers, there is a high unexplained 
incidence of PAH; PAH is now a recognized complication of bone-marrow transplantation for leukemia 11, 
chronic myeloproliferative disorders 12, or in the treatment of malignant infantile osteopetrosis 13.  
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 On the other hand, serotonin (5-Hydroxytryptamine, 5-HT) is associated to the pathogenesis of PAH 
14
. Therapeutic drugs with PAH as a side effect, like the amphetamine derivative and anorexigen 
dexfenfluramine, are potent 5-HT releasers acting at 5-HT transporter (SERT) and/or agonists at 5-HT 
receptors (5-HTRs) 15. An over-expression of 5-HT2BRs is observed in PAH 16. Blockade of 5-HT2BRs 
using independent approaches, either genetic (5-HT2BR knockout mice; 5-HT2B-/-) or pharmacologic (5-
HT2B antagonist RS-12744) inactivation, completely prevented the development of hypoxia-induced 
pulmonary hypertension in mice 16. Using the monocrotaline (MCT)-induced pulmonary hypertension rat 
model, recent studies confirmed that other 5-HT2B antagonists (terguride, PRX-08066, or C-122) 
significantly reduced pulmonary pressure, arterial wall thickening and lumen occlusion but maintained 
cardiac function17-19. Independently, 5-HT was shown to stimulate human bone-marrow stromal cells and 
synergize with other pleiotropic growth factors that promote hematopoietic stem and progenitor cells 20. 
The 5-HT action on hematopoiesis or bone-marrow microenvironment at patho-physiological conditions 
warrant further investigation. 5-HT is a potent vasoconstrictor of pulmonary arteries but also to stimulate 
pulmonary SMC proliferation. It may thus affect various processes associated to pulmonary vascular 
remodeling, but its exact contribution remains unclear.  
 The prognosis of PAH remains unsatisfying 21, although the number of therapeutic options has 
increased over the past years, and several novel therapeutic targets are under active investigation 1. At 
present, currently available vasodilator therapies for PAH, although helpful in improving exercise tolerance 
and quality of life, are only moderately effective in improving survival. These therapies are targeted to 
ameliorate the physiologic consequences of the remodeled pulmonary arterial vasculature and probably do 
not directly alter the underlying defects in the pulmonary vascular remodeling. Here, we investigated a 
possible contribution of 5-HT signaling pathways to bone-marrow-derived progenitors cells in animal 
models of PAH. We found that the expression of 5-HT2BRs restricted to bone-marrow cells is necessary and 
sufficient for pulmonary hypertension to develop via an action at hematopoietic stem cells differentiation. 
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Methods 
Reagents.  
RS-127445, 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, STI-571, 4-[(4-methylpiperazin-1-
yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]-benzamide and all other 
chemicals were reagent grade, purchased from Sigma-Aldrich and Tocris. The radioactive compounds [1,2-
3H]-5-HT binoxalate (specific activity 1.11 TBq/mmol), [methyl,1’,2’-3H]-thymidine (specific activity 4.44 
TBq/mmol) and (6)-[125I]1-(2,5-dimethoxy-4-iodophenyl)- 2-aminopropane hydrochloride ([125I]DOI, 
specific activity 81.4 TBq/mmol) were purchased from NEN Perkin Elmer. Monoclonal rat anti-c-kit 
antibody and the polyclonal rabbit anti-5-HT2BR were from AbCam. 
 
Animals. 
The mice strains used in all experiments, including 5-HT2BRs deficient mice (5-HT2B-/-) are in a 
129S2/SvPAS background 22. Adult (7- 9 week-old) 5-HT2B-/-, and wild-type (WT) control mice (originally 
obtained at Charles River Laboratories, L’Arbresle France) were all derived from heterozygote crosses bred 
at our animal facilities. All mice were maintained according to the EC directive 86/609/CEE, and housed in 
groups of 3-5 of the same genetic background after weaning.  
 
Bone-marrow transplantation. 
As previously described 23, 6 males and 6 females 8 weeks-old WT and 5-HT2B-/- mice were subjected to 
9.5 Gray lethal total body irradiation. The day after, mice were reconstituted by direct intravenous injection 
with 2.5x106 cells of freshly isolated bone-marrow from femurs and tibias of age and sex-matched WT or 5-
HT2B-/- mice. All lethally irradiated and transplanted mice survived revealing the efficiency of bone-marrow 
reconstitution. After 4 weeks of recovery, transplanted mice were then exposed to hypoxia as a validated 
pulmonary hypertension inducer in mice.  
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Pulmonary hypertension induction. 
As previously observed 24, following bone-marrow transplantation, mice were more sensitive to pulmonary 
hypertension inducers. Control and test mice were thus exposed to progressive hypoxia (20 to 10% O2) for 
3 weeks. Control, normoxic mice were kept in the same 12/12 light-dark cycle. The vehicle or drug was 
delivered by miniosmotic pump (Alzet) at the beginning of the hypoxic (or normoxic) treatment.  
 
Cardiovascular evaluations. 
As previously described 16 mice were anesthetized with intraperitoneal ketamine hydrochloride (60 mg/kg) 
and xylazine (8 mg/kg). The arterial pulmonary pressure was estimated by assessing the cardiac right 
ventricular systolic pressure (RVSP), measured by insertion into the heart right ventricle of a 26-gauge 
needle connected to a pressure transducer. The pulmonary artery was cannulated through an incision in the 
right ventricle and perfused with Earle’s balanced salt solution (37°C, 20 cm H2O pressure). The heart and 
lungs were removed and the airways were distended with 10% formaldehyde solution and fixed for 3 days. 
Measurements of the 5-HT2BR expression was performed using 5-HT2R-specific iodinated radioligand (125I-
DOI) sensitive to RS 127445 as previously described 22.  
 
Cell preparations, FACS analysis and sorting. 
Murine bone-marrow cells were recovered and suspended in culture medium, as described 25. Briefly, bone-
marrow cells, flushed from femur and tibia, were resuspended in Hank’s buffer before being passed through 
a 70μm strainer. Cells were then incubated with appropriately labeled antibodies (CD11b, Gr1, CD31, c-kit 
antibodies BD Biosciences, eBioscience) and acquisition was carried out on a FACS CantoII . Murine c-kit+ 
cells (>95% purity) were next sorted electronically using a FACSVantageTM cell sorter (Becton 
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Dickinson). Peripheral blood was collected from mouse tails and cells were counted on a MS9-5 
Hematology Counter (Melet Schloesing Laboratories, Osny, France).  
 
Cell cultures 
Murine hematopoietic progenitors were quantified in MethoCult M3334 (StemCell Technologies) 
supplemented with IL-3, IL-6, SCF and in MethoCult GF H4434 (complete with growth factors), 
respectively. Cells were plated in a final volume of 1 ml at a concentration of 2-5×104 total BM 
cells/culture dish (Falcon 1008) for murine and 5000 CD34+ cells/ml for human progenitors. Colonies were 
scored on day 7 and day 14. All cultures were incubated at 37°C in a humidified chamber under 5% CO2. 
For methylcellulose cultures, human CD34+ cells were cultured in BFU-E/CFU-E medium with EPO, IL-3, 
SCF (Stem Cell 4434) and murine total or c-kit+ cells were cultured in CFU-GEMM/CFU-GM, and CFU-
E/BFU-E medium with IL-3, IL-6, SCF, and EPO (Stem Cell 03434).  
 
Statistics. 
The reported data represent the mean of individual values ± SEM (n = number of individuals at the end of 
treatments as indicated in the text). For simple comparisons, unpaired t test was used. Significance was set 
at P < 0.05. For the groups, statistical comparisons were made by one way ANOVA. When statistical 
significance was attained (P < 0.05), difference between groups was established using the Bonferroni 
multiple comparison test. 
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Results 
Alterations of blood composition in 5-HT2BR mutant mice. Starting from the previous observations that 
5-HT may act on hematopoiesis 20, we first investigated the blood composition of WT and 5-HT2B-/- mice. 
Interestingly, we found a significant decrease in platelet number and increase in circulating granulocyte / 
macrophage population in 5-HT2B-/- compared to WT mice, but not in other parameters, white blood cells, 
red blood cells, mean red blood cell volume, hematocrit, or hemoglobin content (Fig 1a). Flow cytometric 
cell sorting (FACS) was performed using antibodies to identify different populations, Mac-1 (CD11b) for 
monocytes / macrophages, Gr-1 (Gr+) for Granulocytes, PECAM (CD31) for endothelial cells / platelets / 
macrophages and determine the blood cell composition of WT and 5-HT2B-/- mice. Completing our previous 
result, we found a significant reduction in CD11b-/CD31+ population that labeled immature endothelial 
progenitor cells in 5-HT2B-/- mice (Fig 1b). Interestingly, by FACS of peripheral blood mononuclear cells, 
we also identified expression of 5-HT2BRs in c-kit+ (CD117 positive) cells. Importantly, c-kit negative cells 
were negative for 5-HT2BR expression (Fig 1c). Together, these observations support that 5-HT2BRs may 
affect the differentiation of hematopoietic and bone-marrow precursor cells.  
 
Alterations of bone-marrow composition in 5-HT2BR mutant mice. From these blood defects in 5-HT2B-
/-
 mice, we could expect associated alterations in bone-marrow cell composition. Using FACS analysis, we 
determined the bone-marrow composition of WT and 5-HT2B-/- mice (Fig 2). In accordance with our blood 
results, we found in 5-HT2BR mutant bone-marrow a significant increase in Cd11b+/Gr+ that represents 
granulocyte precursors (Fig 2a). Interestingly, this was associated with a significant reduction in Cd11b-
/Cd31+ population that labeled immature endothelial progenitor cells in 5-HT2B-/- mice (Fig 2d). Together, 
these observations support that the lack of 5-HT2BRs alters the differentiation of myeloid precursor cells; 
these precursors may be required for endothelial progenitor cells that have been proposed to participate to 
the development of pulmonary hypertension and pulmonary vascular remodeling 26.  
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Mice with restricted ablation of 5-HT2BRs to bone-marrow are resistant to pulmonary hypertension. 
We investigated if 5-HT2BRs interact with bone-marrow derived stem cells in the development of 
pulmonary hypertension. For this, we generated mice with restricted deletion or rescue of 5-HT2BRs in 
bone-marrow cells using lethal total body irradiation to eliminate all stem cells combined to bone-marrow 
transplantation (Fig 3a- Methods -Supplementary Methods). Strikingly, following this procedure, we 
found that only mice transplanted with WT bone-marrow (i.e. expressing 5-HT2BRs) responded to chronic 
hypoxia in increasing their pulmonary arterial pressure as measured in the heart by the right ventricular 
systolic pressure (RVSP). Irradiated mice transplanted with WT bone-marrow presented a significant 
increase in RVSP, including 5-HT2B-/- host mice after 3 weeks of hypoxia. By contrast, all mice having 
received bone-marrow from 5-HT2B-/- mice, were completely insensitive to hypoxia and never showed any 
sign of RVSP increase, including WT host mice (Fig 3b). Mice with restricted 5-HT2BR deletion to bone-
marrow thus behaved as RS-127445-treated WT, or full 5-HT2B-/- mice 16. To exclude putative bias in these 
results due to the hypoxic model of pulmonary hypertension, we tested the effects of bone-marrow 
transplantation using another animal model of pulmonary hypertension induced by a single MCT injection. 
Strictly similar results were obtained in MCT injected mice: only mice with 5-HT2BR expressing WT bone-
marrow developed an increase in RVSP (Fig S1). These results support a need for 5-HT2BR-dependent 
processes in bone-marrow for the development of pulmonary hypertension.  
 
Lung 5-HT2BR- and c-kit-expressing cells are of bone-marrow origin. Since an increase in lung 5-
HT2BR expression had been previously documented in PAH 16,17, we tested lung 5-HT2BR expression after 
irradiation and bone-marrow replacement. Noteworthy, irradiated 5-HT2B-/- mice having received WT bone-
marrow and exposed to hypoxia showed a similar increase in lung 5-HT2BR expression (about 7 fold) as 
irradiated WT host mice having received WT bone-marrow (Fig 3c-d). To the opposite, WT mice having 
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received 5-HT2B-/- bone-marrow showed no increase in 5-HT2BR expression in the lung after exposure to 
hypoxia as 5-HT2B-/- mice having received 5-HT2B-/- bone-marrow. Strictly similar results were obtained in 
MCT injected mice: only mice with 5-HT2BR expressing WT bone-marrow developed an increase in lung 
5-HT2BR overexpression (Fig S1). These results support that lung cells overexpressing 5-HT2BRs during 
pulmonary hypertension are originating from bone-marrow precursors and not from lung resident cells. 
Since c-kit has been shown to be expressed in lungs of PAH patients 26,27, we completed these 
investigations by performing c-kit and 5-HT2BR immuno-histochemistry of lung tissues. Interestingly, a 
partially overlapping increase in both c-kit and 5-HT2BR expression was observed in small arteries of 
hypoxic WT or 5-HT2B-/- mice transplanted with 5-HT2BR expressing WT bone-marrow, but not with 5-
HT2B-/- bone-marrow (Fig 3c-e). These combinations of bone-marrow transplantation into different 
background confirm that, c-kit and 5-HT2BR expressing cells in the diseased lung are requiring active 5-
HT2BRs in bone-marrow stem cells. In addition, these results support that the initial trigger of pulmonary 
hypertension is originating from bone-marrow progenitors.  
 
Alterations of bone-marrow differentiation after 5-HT2BR inhibition. Previously, 5-HT has been shown 
to enhance the expansion of CD34+ cells to early stem/progenitors (CD34+ cells, colony-forming unit-
mixed [CFU-GEMM]) and committed progenitors (burst-forming unit/colony-forming unit-erythroid 
[BFU/CFU-E] 20,28. We have assessed the effect of 5-HT2BR blockade using the selective antagonist, RS-
127445, during the differentiation of total bone-marrow cell cultures from mice. When mice bone-marrow 
was used in methylcellulose colony-forming assay, we observed a significant reduction in both CFU-
GEMM/CFU-GM and CFU-E/BFU-E colonies with the 5-HT2BR antagonist (Fig. 4a). Similar results were 
obtained when analyzing the clonogenic potential of isolated c-kit+ cells from mice bone-marrow that 
showed also a reduction in both CFU-GEMM/CFU-GM and CFU-E/BFU-E colonies with the 5-HT2BR 
antagonist (Fig. 4b). To validate these findings in humans, we then analyzed the clonogenic potential of 
Launay  p11 
human blood cord CD34+ cells in the methylcellulose colony-forming assay. The most immature CD34+ 
cells isolated from cord blood, were expanded for 14 days in methylcellulose, with or without 5-HT2BR or 
5-HT7R antagonists. The number of BFU-E/CFU-E colonies arising from CD34+ cells was strongly reduced 
(5 fold) upon exposure to the antagonist RS-127445, while no significant difference was observed using the 
5-HT7R antagonist, SB-269970 (Fig. 4c). By flow cytometric purification of bone-marrow cells, we also 
identified expression of 5-HT2BRs in c-kit+ (CD117 positive) cells. Importantly, c-kit- cells, as c-kit+ cells 
after chronic STI-571 treatment (5 weeks, see below) or c-kit+ cells from 5-HT2B-/- mice were negative for 
5-HT2BR expression (Fig 4d). Interestingly, in cultures performed in the presence of GM-CSF, we found 
that the lack of 5-HT2BR reduced the apparition of granulocyte precursors (CD11b+/Gr+) lineage by 50% 
(Fig 4e). Since GM-CSF controls the differentiation of monocyte/macrophages and all granulocytes 29, this 
finding strongly supports a role of 5-HT2BRs at precursor stage differentiation toward these lineages. These 
results confirm the need of the 5-HT2BR action including in human stem cells for early stem/progenitor 
cells and multilineage committed progenitors differentiation of myeloid and erythroid lineages that may 
ultimately participate in the pulmonary hypertension pathogenesis.  
 
Blocking tyrosine kinase c-kit activity prevents pulmonary hypertension and 5-HT2BR 
overexpression. Among compounds that are under investigation for PAH treatment, the tyrosine kinase 
inhibitor, STI-571 has been shown to be effective 30. We thus compared the 5-HT2B selective antagonist 
RS-127445 with STI-571 in their ability to prevent pulmonary hypertension in the mouse hypoxic model 
and found they were both equally effective for tested parameters (Fig. 5a, Fig S2a-d). However, we found 
that only STI-571 was able to prevent the increase in lung 5-HT2BR expression (Fig. 5b). We therefore 
investigated the kinetic in establishment of hypoxic pulmonary hypertension with that of 5-HT2BR 
overexpression. Interestingly, we found that STI-571 was able to prevent both the increase in RVSP and the 
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5-HT2BR overexpression with similar kinetic (Fig 5c,d). These results support an action of both inhibitors at 
a common pathway that ultimately participate in the pulmonary hypertension pathogenesis.  
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Discussion 
Both 5-HT and bone-marrow-derived stem cells have been shown to participate to some extent in PAH. Our 
work establishes, for the first time, a causal link between these two issues by showing (i) the initial 
functions in pulmonary hypertension of 5-HT2BR restricted to bone-marrow cells, (ii) the contribution to 
stem cells differentiation/proliferation of 5-HT2BRs, and (iii) the critical functions of bone-marrow-derived 
cells for pulmonary hypertension development.  
 Several independent investigations have described a mobilization of bone-marrow-derived cells 
during pulmonary hypertension 2. Not only cells expressing c-kit are mobilized from bone-marrow in the 
circulation in response to hypoxia, but they are also found in the remodeled lung vessel wall in PAH 
(7,8,12,24,31 and Fig 3). Activation of c-kit was reported as necessary for mobilization of reparative bone-
marrow progenitor cells 32 and for the remodeling of blood vessels from these progenitor cells 3,27. 
Recently, a role of c-kit+ progenitors in hypoxia-induced vascular remodeling 26,33 was evidenced: stromal 
derived factor-1 (SDF-1/CXCL12) and its receptors CXCR4 and CXCR7 have been shown to be critical for 
homing of hematopoietic c-kit+ progenitor cells in the perivascular niche, including in chronic hypoxia-
exposed mice. These mice showed increased lung expression of CXCR4, CXCR7 and CXCL12, associated 
with significantly increased RVSP, vascular remodeling and perivascular c-kit+/sca-1+ progenitor cell 
accumulation 26. In humans, pulmonary arterial lesions are also associated with expression of CXL12 that 
may recruit c-kit+ cells 27. As we previously reported 16, 5-HT2BRs were found overexpressed (as in mice) 
on human vascular SMC layer in lungs from PAH patients and at least partially colocalized with SMC 
alpha-actin 17. Independently, c-kit was shown to colocalize partially with SMC alpha-actin 26. We show, 
here, that c-kit and 5-HT2BR staining are also partially overlapping in hypoxic lung arteries, supporting a 
common link to SMC lineage. Further work will be need in order to clarified the exact contribution of these 
different partners into vascular remodeling during PAH. 
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 STI-571 is a protein–tyrosine kinase inhibitor, which selectively blocks Abl, c-kit and PDGFR 34, but 
has no 5-HT2BR agonist or antagonist properties (see supplementary data of reference 35). Expression of 
PDGFR was found to be significantly increased in lung tissue from pulmonary arterial hypertension 
patients and beneficial action of STI-571 has been proposed to act directly at lung PDGFR 36, which is well 
known to mediate SMC proliferation. However, in experimental vascular injury, expression of PDGFRβ by 
medial SMCs is upregulated only several days after vascular injury 3, while c-kit+ cells appear within the 
vessel medial wall by the first day and early intervention with STI-571 can significantly attenuate intima 
hyperplasia formation. Finally, the STI-571-mediated inhibition of hyperplasia appears to act through the c-
kit pathway, since the blocking anti-c-kit receptor monoclonal antibody ACK2 generated similar results 3. In 
the present work, we show that the 5-HT2BR-overexpression in lungs is fully prevented by STI-571 
treatment or by lack of 5-HT2BR in bone-marrow, both of which can hardly be explained only by a direct 
inhibition of lung resident cells expressing PDGFR. Our result strongly supports that cells, which give rise 
to 5-HT2BR expressing cells in lungs, are c-kit+ progenitor cells originating from bone-marrow, although 
contribution of other receptors-tyrosine kinase sensitive to STI-571 cannot be excluded.  
 Plasma 5-HT is increased in PAH patients, even after lung transplantation 37, which suggests that 5-
HT either is an extra pulmonary causative factor in PAH or is associated with such a factor. Deletion of 
tryptophan hydroxylase 1 (the limiting enzyme in peripheral 5-HT synthesis), SERT or 5-HT1BRs reduces 
pulmonary vascular remodeling and hypoxic pulmonary hypertension 38. Locally, 5-HT has been shown to 
be a potent vasoconstrictor of isolated pulmonary arteries but also to stimulate pulmonary SMC 
proliferation. It has thus been implicated in various processes associated to pulmonary vascular remodeling. 
We found here 5-HT2BR expression in both c-kit+ bone-marrow-derived cells and c-kit+ circulating blood 
cells. In addition, the results of bone-marrow transplantation establish for the first time that 5-HT2BR-
expressing cells in hypertensive lungs are exclusively of extra-pulmonary origin probably deriving from c-
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kit+ bone-marrow precursors. These results clearly reveal that the initial requirement for 5-HT2BRs in PAH 
is extrinsic to the lung and bone-marrow-derived, independently of resident lung cells.  
 Although likely not instructive in stem cell lineages, 5-HT may rather modulate the balance between 
different lineages by participating at the proliferation and/or survival of specific lineage via its receptors 
(Fig 6). Similar to what we found here using 5-HT2BR antagonist RS-127445, a decrease in colony-forming 
capacity was observed with STI-571 with inhibition of both CFU-GEMM and BFU-E formation attributed 
to a reduction of cell proliferation and/or an apoptotic effect 39. In addition, we found 5-HT2BR expression 
in c-kit+ bone-marrow cells, but not in these cells after STI-571 treatment. To the opposite, 5-HT 
significantly enhanced the expansion of CD34+ cells to early stem/progenitors (CFU-GEMM) and 
committed progenitors (BFU/CFU-E) 20. Recently, the absence of 5-HT was shown to reduce erythroid 
precursors in bone-marrow via 5-HT2A and 5-HT2BRs since a 5-HT2 agonist, PNU 22394, produced the 
same proliferative effect on erythroid precursors as observed with 5-HT 28. At early stages of 
megakaryocytopoiesis, 5-HT regulates proliferation and survival by antiapoptotic effects on 
megakaryoblastic cells 40. On megakaryocytic cell line HEL, pretreatment with 5-HT protected subsequent 
nitric oxide-induced apoptosis 41. We previously showed that 5-HT2BRs were required for proliferation of 
embryonic and survival of newborn cardiomyocytes via regulation of mitochondrial membrane 
permeability, caspase activation, and Akt/ERK1/2 pathways 42. Combined with these observations, the 
present data clearly highlight the importance of 5-HT via 5-HT2BRs at various levels of the myeloid 
lineages as summarized on the scheme (Fig 6). Our data support their requirement for proliferation/survival 
after the c-kit-dependent mobilization of precursors from bone-marrow.  
 Bone-marrow progenitor cell mobilization is a physiological response to hypoxic conditions 4,6, and 
altered circulating bone-marrow-derived precursors have been reported in PAH as contributors to vascular 
remodeling 7,8,24,31. Patients with myeloproliferative diseases often develop PAH, but this secondary form of 
PAH has been reported to resolve with treatment of the underlying myeloproliferative process 43. Other data 
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highlight a potential interdependence of dysregulated hematopoiesis and abnormal pulmonary vascular 
endothelial behavior that may play a key role in the development of PAH 10. It was previously demonstrated 
that cells from the mononuclear lineage could differentiate into endothelial- and SMC-like cells at injured 
vessels 44-47 and that circulating precursors of this lineage can contribute to hypoxia-induced pulmonary 
vascular remodeling 6. In this context, a stimulus-dependent generation of pro-angiogenic and bone-
marrow-derived early progenitors could be required for physiological repair response to ongoing pulmonary 
vascular shear stress and endothelial injury. That this process ultimately contribute to the abnormal 
proliferation of SMC and endothelial cells leading to progression of pulmonary hypertension was still 
hypothetical 9. We validate here the interdependence of dysregulated hematopoiesis and abnormal 
pulmonary vascular remodeling that play key roles in the development of PAH.  
 Studies in patients and experimental models have led to a dichotomy of views regarding the role of 
bone-marrow progenitor cells in PAH. On the one hand, a relative deficiency of circulating endothelial 
precursor cells might contribute to pulmonary vascular pathology; and the transfusion of native autologous 
or genetically modified endothelial precursor cells could offer a novel cell-based therapy; long-term 
pharmacologic augmentation of endogenous progenitors represents an additional strategy. On the other 
hand, dysfunctional, apoptotic-resistant, and proliferative pulmonary vascular cells are implicated in the 
pathogenesis of PAH 12; and the inclusion of progenitor cells in vascular lesions may have adverse long-
term consequences 9. Our work reveals that the absence of 5-HT2BRs generates permanent alterations of 
blood and bone-marrow composition in myeloid lineages and in particular, in endothelial/SMC progenitors. 
The present finding clearly supports a role of 5-HT2BRs in the maturation of different myeloid progenitors 
including immature endothelial/SMC precursors required for PAH pathogenesis.  
 Our work supports the concept that bone-marrow-derived cells contributing to pulmonary vascular 
remodeling may be the link between PAH and bone-marrow-related hematological disorders 4. By 
demonstrating a causal role for 5-HT2BRs in bone-marrow progenitors, which controls precursor cells 
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contributing to pulmonary hypertension vascular remodeling, this work switches the attention about PAH 
initiating events from an intrinsic lung issue to a bone-marrow originating problem. 
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Figure legends 
Figure 1:  
(a) In total blood, the number of white blood cells (WBC), red blood cells (RBC), the mean red blood cell 
volume (MRBCV), the hematocrit, and the hemoglobin content were not different among genotypes, while 
the number of platelets was significantly reduced and the percent of neutrophil/granulocyte (%N/Gr) 
significantly increased in the blood of 5-HT2B-/- mice. Values are means±sem (n=20, P < 0.05). Any 
statistical difference by unpaired t test vs. control is indicated by ***P <0.001; **P <0.01. (b) Flow 
cytometric analysis of blood cells using cell-surface markers allows identification of different populations. 
Mac-1 (CD11b) for monocytes/macrophages, Gr-1 (Gr+) for Granulocytes, PECAM (CD31) for endothelial 
cells / platelets / macrophages antibodies were used to identify lin+ cells or late multipotent progenitors. In 
blood, while the number of c-Kit+Lin- cells was unaffected, the 5-HT2B-/- mice had reduced number of 
CD11b-/CD31+, immature endothelial progenitors. Values are means±sem (n=10, P < 0.05). Any statistical 
difference by unpaired t test vs. control is indicated by ***P <0.001. (c) By flow cytometric purification of 
peripheral blood mononuclear cells, we first identified expression of 5-HT2BRs in c-kit+ cells but not in c-
kit- cells (28.4±7.9 fmoles/mg protein vs. 4.6±3.2, p<0.05, n=14). Any statistical difference by unpaired t 
test vs. control is indicated by ***P <0.001. 
 
Figure 2:  
(a) In bone-marrow of 5-HT2B-/- mice, the number of CD11b+/Gr+ cells, corresponding to committed 
precursor cells of the monocyte/granulocyte lineage, was significantly increased as shown by the 
distribution of cells by FACS (a-left panel, representative experiment) and quantification in percent of total 
cells (a-right panel, n=3). No modifications of the c-kit+Lin- cells, multipotent stem cells (b) or 
Cd11b+CD31+ cells (c) was observed in bone-marrow of 5-HT2B-/- mice. However, bone-marrow of 5-
HT2B-/- mice present a significant reduction of CD11b-/CD31+, immature committed endothelial/SMC 
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precursor cells (d). Values are means±sem, n=3 independent determinations. Any statistical difference by 
unpaired t test vs. control is indicated by ***P <0.001.  
 
Figure 3:  
 (a) WT mice transplanted with bone-marrow cells from WT or 5-HT2B-/- (WT_WT, WT_KO, respectively) 
and 5-HT2B-/- (KO) mice transplanted with bone-marrow cells from 5-HT2B-/- or WT (KO_KO, KO_WT, 
respectively) were exposed to progressive hypoxia (20% to 10% for 3 weeks). (b) Pulmonary arterial 
pressure as assessed by RVSP increased in mice bearing WT bone-marrow either in WT (WT_WT) or 5-
HT2B-/- (KO_WT) background. Conversely, mice with 5-HT2B-/- bone-marrow into WT (WT_KO) or 5-
HT2B-/- (KO_KO) background did not show any RVSP increase. (c) Immunohistochemistry of c-Kit and 5-
HT2BR. Staining was performed with antibodies against 5-HT2BR (pink; rabbit polyclonal AbCam ) or 
against c-Kit (blue; rat monoclonal AbCam). Scale bars represent 50 µm. (d) Lung 5-HT2BR expression 
(Bmax) increased in mice bearing WT bone-marrow not only in WT (WT_WT) but also in 5-HT2B-/- 
(KO_WT) background. Conversely, not only mice with 5-HT2B-/- bone-marrow into 5-HT2B-/- (KO_KO), 
but also in WT (WT_KO) background did not show any change in lung 5-HT2BR expression compared to 
controls WT (18 fmoles/mg prot) or full 5-HT2B-/- (less than 5 fmoles/mg prot). (e) Similarly, the pulmonary 
perivascular c-kit+ bone-marrow derived progenitor cell recruitment induced by hypoxia was higher in mice 
with WT bone-marrow to WT (WT_WT) or 5-HT2B-/- (KO_WT) background as revealed by quantification 
of the immuno-labeling. Values are means±sem (n=12, P < 0.05). Lines are normoxic values. Any 
statistical difference by one way ANOVA followed by Bonferroni post hoc test is indicated by ***P 
<0.001.  
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Figure 4:  
(a) In mouse bone-marrow cells, methyl cellulose cultures, RS-127445 reduced CFU-GEMM/CFU-
GEM/BFU-E/CFU-E (n = 3 independent cultures). Statistical difference by unpaired t test vs. control is 
indicated by ***P <0.001, *P <0.05 vs. Vehicle. (b) Similarly, in c-kit+ bone-marrow cells, methyl 
cellulose cultures, RS-127445 reduced CFU-GEMM/CFU-GEM/BFU-E/CFU-E (n = 3 independent 
cultures). Statistical difference by unpaired t test vs. control is indicated by ***P <0.001, *P <0.05 vs. 
Vehicle. (c) On methyl cellulose cultures of human blood cord CD34+ cells, the 5-HT2BR antagonist RS-
127445 significantly reduced expansion of BFU-E/CFU-E, burst-forming unit/colony-forming unit-
erythroid, but not the 5-HT1BR antagonist SB-269970 (n = 4 independent cultures). Any statistical 
difference by unpaired t test vs. control is indicated by ***P <0.001 vs. Vehicle, #P <0.05 vs. SB-269970. 
(d) After flow cytometric purification of bone-marrow cells, expression of 5-HT2BRs was detected in c-kit+ 
(CD117 positive) cells (n=8), but remained undetectable in c-kit- cells (n=5), c-kit+ cells after STI-571 (STI) 
treatment (n=6) or c-kit+ cells from 5-HT2B-/- mice (n=5). (e) On ex vivo expansion of total bone-marrow 
cells in the presence of GM-CSF driving the monocyte/macrophages and all granulocytes differentiation, 
the lack of 5-HT2BRs significantly reduced the number of CD11b+/Gr+ cells (n = 3-5 mice of each 
genotype). Any statistical difference by unpaired t test vs. control is indicated by ***P <0.001 vs. 5-HT2B+/+ 
culture.  
 
Figure 5: 
Groups of 10 WT mice were exposed to hypoxia (10% 02) for 5 weeks (H), and in the presence of either 
RS-127445 (0.5mg/kg-HRS), or STI-571 (1mg/kg-HST) and compared to normoxic mice (0). (a) The 
significant increase in hypoxia-induced RVSP was totally prevented by RS-127445 or STI-571. (b) Chronic 
hypoxia increased significantly the maximal number of lung 5-HT2BR specific binding sites (Bmax), which 
was not significantly prevented by RS-127445, but STI-571 did prevent this increase. (c) Groups of 10 WT 
Launay  p27 
mice were exposed to hypoxia (10% 02) for 0 to 35 days in the presence of vehicle (Veh) or STI-571 (STI) 
(1mg/kg). The significant increase in hypoxia-induced RVSP observed at 21 and 35 days was totally 
prevented by STI-571 with similar kinetic. (d) Chronic hypoxia increased significantly the maximal number 
of lung 5-HT2BR specific binding sites (Bmax) at 21 and 35 days, which was significantly prevented by 
STI-571 with similar kinetic. Values are means±sem (n=10, P < 0.05) and are representative of at least two 
independent experiments. Straight lines are normoxic values. Any statistical difference by one way 
ANOVA followed by Bonferroni post hoc test vs. normoxic untreated control values is indicated by * and 
vs. chronic hypoxia values by a #; ***P <0.001; **P <0.01; *P <0.05; ##P <0.01; #P <0.05. 
 
Figure 6: 
Working model illustrating the present findings. This work implicates 5-HT2B receptors at different levels 
of the myeloid lineage. The absence of 5-HT2BRs in mutant mice (2B-/-) leads to a reduction in ( ) platelets 
and immature endothelial progenitors and lineages but to an increase () in granulocyte precursors and 
lineages. 






